Clinical evidence Exashape

Medical literature is dense by necessity, but that doesn’t mean it has to be inaccessible. We created these animated visualisations to make the study’s key findings easier to absorb at a glance: patient demographics, complication rates, quality-of-life outcomes, and surgical workflow. No data has been altered or embellished. All figures, percentages, and direct quotes are taken verbatim from the published paper.

Our goal is to support awareness of emerging surgical techniques among clinicians, patients, and the wider healthcare community, not to replace the original research. We strongly encourage readers to consult the full study via the DOI above.


Article content
Article content
Article content
Article content

Patients’ age ranged from 38 to 55 (mean age 48 years) and they presented a mean BMI of 22.0 kg/m² (range 18–24.5 kg/m²). None of them presented relevant comorbidities but one was a light smoker. Thirty-seven Exashape™ Bioshield Pocket membranes were used: medium size in 12 cases and large size in all the other cases. Of twenty-one patients enrolled for this study, only five patients had complications: four resolved after surgical revision of scars and one with implant loss.

— Results, p. 53


Article content

After surgery, scores for overall satisfaction with breasts, psychosocial well-being, and sexual well-being were all significantly increased (p < 0.05). Health-related quality-of-life was assessed comparing the preoperative and postoperative BREAST-Q scores. As shown by the data collected at BREAST-Q, all patients are satisfied with the type of reconstruction performed and the result obtained. Therefore, with the current results, even if still in the initial phase, we feel we can conclude that the Exashape™ can give a good aesthetic and functional result, allowing the woman to feel comfortable in their daily routine.

— Results & Discussion, p. 54–56

Article content

The design of this membrane for DTI Pre-pectoral reconstruction known as Bioshield Pocket™ allows anterior coverage of the implant in less than five minutes creating an additional layer, without the need for adaptation procedures or redundant biological mass, reducing operative time, risk of accidental damage to the silicone implant and limiting protracted handling, with the associated risk of contamination that brings. The implant and mesh assembly can be positioned within the breast skin flap pocket, even without the need for chest wall sutures.

— Introduction, p. 52

Exashape™ Bioshield Pocket allowed a considerable reduction of surgical time in implant positioning, lowering exposure time and risk of infection. It also reduces the risk of implant damage during suturing. Although further studies would be useful to validate our result, we can say that Exashape™ has proved to be useful in breast reconstruction, allowing a good aesthetic and functional result.

— Conclusions, p. 56


The animations in this article are based entirely on data from the following peer-reviewed publication:

Mazzocchi M, Sigorini G, Cerciello E, Barberini F. “The use of Exashape™ Bioshield Pocket in prepectoral breast reconstruction: a preliminary experience.” Plastic, Reconstructive & Regenerative Surgery (PRRS) 2022;1:51–57. DOI: 10.57604/PRRS-064

The study was conducted at the Breast Unit, University of Perugia (Azienda Ospedaliera Perugia, Italy), and approved by the Institutional Ethics Committee (approval no. 325/2021). All patients provided written informed consent.

Copyright & open access

The original study is published under a CC-BY-NC-ND 4.0 International licence (Creative Commons Attribution-NonCommercial-NoDerivatives). This summary is a non-commercial educational use. Quotes reproduced from the paper are attributed and used solely for commentary and informational purposes. All rights to the original work remain with the authors and Pacini Editore Srl.

Medical device notice

Exashape™ Bioshield Pocket is a regulated medical device. Its availability, approved indications, and regulatory status vary by country. References to this product do not imply regulatory approval in any specific jurisdiction. Consult local regulatory guidance and device labelling before clinical use.